UroGen Pharma/$URGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Ticker

$URGN
Primary listing

Industry

Biotechnology

Employees

234

ISIN

IL0011407140

UroGen Pharma Metrics

BasicAdvanced
$622M
-
-$3.04
0.67
-

What the Analysts think about UroGen Pharma

Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.

Bulls say / Bears say

Scotiabank initiated coverage of UroGen Pharma with a 'Sector Outperform' rating and a $23.00 price target, indicating strong confidence in the company's growth prospects. (nasdaq.com)
UroGen Pharma reported Q3 2024 revenues of $25.2 million, surpassing consensus estimates and reflecting a 20% year-over-year increase, demonstrating robust financial performance. (nasdaq.com)
The company's lead candidate, UGN-102, shows promise in treating low-grade intermediate-risk non-muscle invasive bladder cancer, with significant clinical trial success and a PDUFA date set for June 13, 2025. (seekingalpha.com)
UroGen Pharma reported a Q4 2024 loss of $0.80 per share, missing consensus estimates and indicating ongoing financial challenges. (nasdaq.com)
Goldman Sachs maintains a 'neutral' rating on UroGen stock, suggesting limited upside potential in the near term. (investing.com)
Insider selling activity, including the sale of 4,551 shares by insider Mark Schoenberg, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

UroGen Pharma Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

UroGen Pharma Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $URGN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs